Neurocrine Biosciences' NBI-1117568 in Phase 2 for schizophrenia shows symptom improvement with no serious side effects.
Neurocrine Biosciences reports positive Phase 2 data for NBI-1117568 in adults with schizophrenia, partnered with Nxera Pharma. The drug candidate showed significant improvement in symptoms and no serious side effects. Shares of the company decreased, potentially related to a recent FDA decision on another drug.
August 28, 2024
66 Articles